UNSPSC 51101930: Enpiroline

This classification denotes an antimalarial agent with the molecular formula C19H18F6N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 8M7Y72EP9K chemically known as 4-pyridinemethanol, .alpha.-(2-piperidinyl)-2-(trifluoromethyl)-6-(4-(trifluoromethyl)phenyl)-, (r*,r*)-(+/-)- but generally known as enpiroline, which bears US NIH Compound Identifier 3033333. European Medicines Agency schedules Enpiroline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06545MIG.

UNSPSC 51101930 Enpiroline is a Commodity code capturing pharmaceutical and over-the-counter health products that state and local governments procure for emergency response, community health, and employee benefit programs. Recent solicitations show state and local buyers acquiring naloxone kits and drug deactivation systems for community health deployment, medical and first aid supplies for fire department rescue operations, generic pharmaceuticals and OTC products through cooperative purchasing arrangements, and direct-to-manufacturer prescription fulfillment capabilities for health benefit programs. The issuing bodies span county health departments, municipal fire departments, state health agencies, and multi-state cooperative purchasing alliances, reflecting a broad mix of health and emergency-response end users rather than a concentrated buyer base.

Geographic activity centers on Florida, Texas, and Minnesota with cooperative purchasing extending to Oregon and other participating jurisdictions. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to its Community Health Building. The City of Tampa released ITB 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies totaling an estimated $700,000 for its Fire Department Rescue Division, designated as a sheltered market opportunity exclusively for certified Small Local Business Enterprises with a 5 percent bid discount not to exceed $10,000. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026, due April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with contract effectiveness July 1, 2026 and evaluation weighted 75 percent on price competitiveness.